arrow
L

Larry A. Harshyne

Thomas Jefferson University
H指数:23
被引数:7,296

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Survival Outcomes in Head and Neck Squamous Cell Carcinoma Receiving Neoadjuvant Immunotherapy

中性粒细胞与淋巴细胞比值作为接受新辅助免疫治疗的头颈鳞状细胞癌患者生存结局的预后因素

2026-03-220
OAAI
Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck

Nivolumab和ipilimumab联合放疗治疗高危局部晚期头颈部鳞状细胞癌

2023-08-035
OAAI
IL-8 correlates with nonresponse to neoadjuvant nivolumab in HPV positive HNSCC via a potential extracellular vesicle miR-146a mediated mechanism

IL-8通过潜在的细胞外囊泡miR-146a介导的机制与HPV阳性HNSCC对nivolumab的新辅助治疗无反应相关

2023-07-044
OAAI
Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma

他达拉非增强可切除头颈部鳞状细胞癌新辅助Nivolumab的免疫特征

2021-12-1430
OAAI
Spatial distribution of CD8+and FoxP3+in a window of opportunity for durvalumab (MEDI4736) plus metformin trial in squamous cell carcinoma of the head and neck (HNSCC)
2021-09-011
OAAI
Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma
2021-01-2635
OA
Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect
2020-12-0230
OAAI